Related references
Note: Only part of the references are listed.Tadalafil Therapy for Pulmonary Arterial Hypertension
Nazzareno Galie et al.
CIRCULATION (2009)
Persistent eNOS activation secondary to caveolin-1 deficiency induces pulmonary hypertension in mice and humans through PKG nitration
You-Yang Zhao et al.
JOURNAL OF CLINICAL INVESTIGATION (2009)
Bosentan for Treatment of Inoperable Chronic Thromboembolic Pulmonary Hypertension
Xavier Jais et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2008)
Quantification of F-2-isoprostanes as a biomarker of oxidative stress
Ginger L. Milne et al.
NATURE PROTOCOLS (2007)
Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension
Vallerie V. McLaughlin et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2006)
Increased plasma monocyte chemoattractant protein-1 level in idiopathic pulmonary arterial hypertension
T Itoh et al.
RESPIROLOGY (2006)
Sildenafil citrate therapy for pulmonary arterial hypertension
N Galiè et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Decreased exhaled nitric oxide in pulmonary arterial hypertension - Response to bosentan therapy
RE Girgis et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2005)
Pivotal role for endothelial tetrahydrobiopterin in pulmonary hypertension
JP Khoo et al.
CIRCULATION (2005)
ATS/ERS recommendations for standardized procedures for the online and offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide, 2005
American Thoracic Society et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2005)
Oxidant stress but not thromboxane decreases with epoprostenol therapy
IM Robbins et al.
FREE RADICAL BIOLOGY AND MEDICINE (2005)
Decreased whole body endogenous nitric oxide production in patients with primary pulmonary hypertension
EAG Demoncheaux et al.
JOURNAL OF VASCULAR RESEARCH (2005)
Oxidative stress in severe pulmonary hypertension
R Bowers et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2004)
Long-term follow-up of a patient with mild tetrahydrobiopterin-responsive phenylketonuria
R Cerone et al.
MOLECULAR GENETICS AND METABOLISM (2004)
Cellular and molecular pathobiology of pulmonary arterial hypertension
M Humbert et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2004)
Tetrahydrobiopterin as an alternative treatment for mild phenylketonuria
AC Muntau et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension - Comparison with inhaled nitric oxide
E Michelakis et al.
CIRCULATION (2002)
Tetrahydrobiopterin enhances forearm vascular response to acetylcholine in both normotensive and hypertensive individuals
Y Higashi et al.
AMERICAN JOURNAL OF HYPERTENSION (2002)
Effect of chronic infusion of Epoprostenol on echocardiographic right ventricular myocardial performance index and its relation to clinical outcome in patients with primary pulmonary hypertension
I Sebbag et al.
AMERICAN JOURNAL OF CARDIOLOGY (2001)
Plasma markers of endothelial dysfunction in pulmonary hypertension
G Cella et al.
CHEST (2001)
Increased lipid peroxidation in patients with pulmonary hypertension
JL Cracowski et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2001)
Tetrahydrobiopterin improves endothelial dysfunction in coronary microcirculation in patients without epicardial coronary artery disease
S Setoguchi et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2001)
Sildenafil inhibits hypoxia-induced pulmonary hypertension
L Zhao et al.
CIRCULATION (2001)
Tetrahydrobiopterin improves endothelium-dependent vasodilation in chronic smokers -: Evidence for a dysfunctional nitric oxide synthase
T Heitzer et al.
CIRCULATION RESEARCH (2000)
Share Paper
